1- Debouverie M, Rumbach L, Clavelou P, Données épidémiologiques et analyse de l’offre de soins de la sclérose en plaques en France. Rev Neurol 2007;163(6-7):637–45
2- McDonald WI1, Compston A, Edan G, Goodkin D, et a.l Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul;50(1):121-7.
3- Ascherio A1, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007 Apr;61(4):288-99.
4- Polman CH1, Reingold SC, Banwell B,and all. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaAnn Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366.
5- Sclérose en plaques. Guide ALD n° 25, HAS, septembre 2006. http://www.has sante.fr/portail/
6- Consensus Conference Organized by the French Federation for Neurology », Revue Neurologique, 2001, n° 157, pp. 902-1192.
7- Kappos L, Freedman MS, Polman CH, and al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.2009 Nov;8(11):987-97. 8 - Mowry EM1, Pesic M, Grimes B, Deen S, Bacchetti P, Waubant E. Demyelinating events in early multiple sclerosis have inherent severity and recover. Neurology. 2009 Feb 17;72(7):602-8.
Étude & pratique
Apnées du sommeil : quel impact de la ventilation sur la mortalité ?
Cas clinique
L’épulis
Recommandations
Bilan d’un trouble mictionnel chez l’homme
Cas clinique
La bisalbuminémie